Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
Sign Up to like & getrecommendations! Published in 2017 at "Stem Cell Reports"
DOI: 10.1016/j.stemcr.2017.03.007
Abstract: Summary A point mutation in the BRAF gene, leading to a constitutively active form of the protein, is present in 45%–60% of patients and acts as a key driver in melanoma. Shortly after therapy induction,… read more here.
Keywords: melanoma; melanoma derived; tumorigenicity; derived ipccs ... See more keywords